Key Takeaways
- •Retatrutide is a single peptide engineered for agonist activity at three receptors: GIP, GLP-1, and glucagon 1.
- •What remains unresolved is access.
- •Retatrutide is an investigational molecule.
Retatrutide is a single peptide engineered for agonist activity at three receptors: GIP, GLP-1, and glucagon 1. That triple mechanism separates it from tirzepatide, which acts on GLP-1 and GIP only 2, and from GLP-1-only agents such as semaglutide. Peer-reviewed work describes the same three-receptor profile independently 3, so the pharmacology itself is not in dispute.
What remains unresolved is access. No published study establishes a Canadian regulatory pathway for retatrutide, and no licensed Canadian source for patient access has been documented in the primary literature. Health Canada status and the question of whether any Canadian site is actively recruiting are likewise unanswered by published research; resolving either would require a regulatory filing record or a registered trial listing, not a supplier page. Trial eligibility, contraindication incidence, and monitoring parameters are addressed in the sections below, with the limits of each stated plainly.
Canadian access status and what is not established
Retatrutide is an investigational molecule. It is not a licensed medicine in Canada, and no part of the published record reviewed here documents a Health Canada approval pathway, a Notice of Compliance, a Drug Identification Number, or a market authorization for it. That is the starting point for anyone evaluating a Canadian listing that presents retatrutide as a purchasable therapeutic product.
What the clinical record actually contains
The most frequently cited efficacy figure comes from a peer-reviewed study reporting that retatrutide at 12 mg once weekly produced weight loss of up to 22.1% after 48 weeks 7. That number circulates widely in Canadian retail listings and social media, usually stripped of its context. The same peer-reviewed review noted that adverse events were frequent among GLP-1 RA users compared with placebo 7, and that no head-to-head randomized controlled trials were available for the agents reviewed 7. So the 22.1% figure is not a comparison against semaglutide or tirzepatide under controlled conditions. It sits alongside a tolerability signal that any researcher characterizing the compound should treat as part of the dataset, not as an afterthought.
Trial geography matters for Canadian readers trying to place the evidence. The study in question was conducted at 42 research and health-care centres in the USA 1. No Canadian site is documented in that record. That does not mean Canadian patients were excluded from all retatrutide research, but it does mean the trial infrastructure described in the peer-reviewed literature is American, and Canadian clinical availability cannot be inferred from it.
A separate peer-reviewed commentary argues that rapid progress in developing highly efficacious GLP-1 medicines is expected to provide greater opportunities for personalized medicine in cardiometabolic disorders 5. That is a forward-looking expert opinion about the class, not a statement about retatrutide's regulatory status in any jurisdiction, and it should not be read as one.
The retail access question, answered directly
Canadian buyers routinely encounter listings that imply lawful patient supply: an add to cart button, an in stock badge, a quick view panel, a new arrival tag, a stated milligram strength such as retatrutide (10mg). None of those interface elements is evidence of authorization. A cart button proves a payment processor exists. An in stock indicator proves inventory exists somewhere. A quick view panel proves a product page was built. A new arrival label proves a listing was created recently. None of them establishes that a compound may lawfully be dispensed to a patient in Canada.
To prove lawful patient supply in Canada, a seller would need to produce at minimum: a Health Canada market authorization or a documented pathway under which the product is legally supplied, such as a clinical trial authorization or a Special Access Programme approval; a licensed Canadian importer or manufacturer identified on the label; a Drug Identification Number or equivalent regulatory identifier; and a named Canadian licence holder accountable for release. Absent those items, a Canadian listing describes a research chemical, not a therapeutic.
This article cannot verify any licensed Canadian dispensing source for retatrutide, and it cannot verify a Health Canada approval pathway, because no such authorization appears in the published record. That is a statement about the absence of documentation, not proof that no application is pending. A pending submission is not an approval, and a listing that cites a pending submission is citing an intention.
What this means for procurement
For laboratory buyers, the practical distinction is between a compound sold for in vitro and analytical work and a compound represented as a medicine. The first is a reagent with a certificate of analysis, a purity figure, and a storage specification. The second requires the regulatory chain described above. Canadian suppliers operating in the research space should be able to show batch documentation and testing records; the Quality and Testing page describes what that documentation typically covers. Storage conditions for lyophilized material are covered in the Peptide Storage Guide.
What is not established, and should be stated plainly: no published study has measured Canadian patient access to retatrutide, no Health Canada authorization has been documented, and no head-to-head trial places it against an approved comparator 7. Researchers should treat any Canadian retail listing as a research supply claim until the regulatory documents above are produced.
Evidence base, study designs, and how to read the clinical data
The retatrutide clinical literature available for evaluation is dominated by two registered phase 2 trials, and the distinction between what those trials measured and what a reader might assume they measured matters more than the headline numbers.
The two registered trials
The first is registered at ClinicalTrials.gov under NCT04867785 1. The second carries the registration number NCT04881760 4. Both were funded by Eli Lilly and Company, the compound's originator 1. That funding relationship is not a disqualifier, but it does shape how the published reports should be read: the sponsor designed the protocols, held the data, and in most cases employed the authors who wrote them up. Independent replication of either trial has not been published.
What the obesity study actually showed
The 48-week phase 2 obesity study reported weight reductions of 22.8% and 24.2% at retatrutide 8 mg and 12 mg respectively 4. Those are the two figures most often quoted in sourcing discussions, and they deserve context. They come from a phase 2 design, which means modest enrollment, a fixed treatment window, and endpoints chosen to establish a signal rather than to support a label. Forty-eight weeks is short relative to the multi-year exposure that a chronic weight-management agent would see in practice. The trial also did not test the doses against a marketed comparator in a head-to-head design, so the percentages describe performance against baseline and placebo, not against any other incretin-based therapy.
Population and enrollment
The companion trial enrolled 338 adults, of whom 51.8% were men 3. That is a useful anchor for anyone assessing generalizability. A phase 2 cohort of that size, roughly balanced by sex, is large enough to detect a strong efficacy signal and too small to characterize uncommon adverse events, subgroup-specific responses, or interactions with the comorbidities that dominate real treatment populations. Readers evaluating early-phase data should treat effect sizes from cohorts of this scale as directional. The confidence intervals around subgroup estimates in a trial of 338 will be wide, and any subgroup finding reported from it should be treated as hypothesis-generating rather than confirmatory.
Where the evidence runs out
Several things a researcher or procurement reviewer would reasonably want are simply not documented in the published record. No published study has measured retatrutide's stability under specific storage or handling conditions outside the sponsor's own formulation work. No published head-to-head comparison against semaglutide or tirzepatide exists. Long-term cardiovascular and safety outcomes, the kind that require thousands of patient-years, are not available at phase 2.
Two gaps are specific to the Canadian context. First, no published study has identified Canadian sites recruiting for retatrutide trials, and the registrations cited above do not establish Canadian enrollment. Second, no regulatory pathway documentation for retatrutide in Canada has been published: Health Canada has not issued a notice of compliance, a priority review designation, or a public submission record that can be cited. Anyone claiming a Canadian approval timeline is extrapolating from the US and EU pipelines, not from Canadian filings.
Reading the numbers responsibly
The practical takeaway for a technical reader is to separate three categories. Established: the compound produces large weight reductions at 8 and 12 mg over 48 weeks in a sponsored phase 2 obesity trial 4. Plausible but unverified: that the effect persists, that it generalizes beyond the enrolled cohort 3, and that it holds against active comparators. Unknown: Canadian trial availability, Canadian regulatory status, and long-term safety. The Research Literacy Guide covers how to weigh phase 2 effect sizes against later-phase replication, and the Peptide Glossary defines the endpoint terminology used in these registrations.
Comparative efficacy versus semaglutide and tirzepatide
The comparison researchers most often ask about is not a comparison that has been run. Retatrutide, semaglutide and tirzepatide have each been studied against placebo or against an active comparator other than each other, and the review literature that pools them treats them as members of a broader drug class rather than as three agents in a single trial. That distinction governs everything below: what follows is largely indirect, and indirect comparisons carry assumptions that head-to-head randomization does not.
What the pooled review evidence actually supports
A peer-reviewed review of GLP-1 receptor agonists and co-agonists concluded that this group of agents is efficacious for weight loss in adults with overweight or obesity who do not have diabetes 7. That is the strongest class-level statement available here, and it is deliberately broad. It covers the drug class, not individual molecules, and it addresses weight loss as an outcome, not glycaemic control, cardiovascular endpoints, tolerability, or durability after discontinuation. The same review identified semaglutide as one of three commercially available agents included in its analysis 7. The practical consequence for anyone reading that review as a ranking is that it was not built to produce one. Three agents entered the analysis; the conclusion was drawn at the level of the class.
Regulatory status shapes what can be compared
The two comparators differ from each other in how they are approved, which matters when a reader tries to line up trial populations. Semaglutide 2.4 mg, given once weekly by subcutaneous injection, was approved for obesity treatment in 2021 6. Tirzepatide holds approvals for glycaemic control in type 2 diabetes and separately for obesity management 6. Retatrutide does not appear in that regulatory picture on the same footing. So a researcher assembling a comparison table is not placing three approved obesity therapies side by side; they are placing two approved agents against a third whose clinical profile is still being characterized in trials.
Where the trial populations diverge
Population differences are the main reason indirect comparisons between these agents should be read cautiously. One trial of the type relevant to this comparison enrolled adults aged 18 to 75 years with type 2 diabetes and a BMI of 25 to 50 kg/m2 1. That is a diabetes population with a defined BMI window, and it is not the same population as adults with overweight or obesity without diabetes, which is the group the class-level review addressed 7. Baseline glycaemic status, concomitant glucose-lowering medication, and diabetes duration all influence how much weight loss a given agent produces in a given trial. Comparing an effect size drawn from a diabetes cohort against one drawn from a non-diabetes cohort, without adjustment, will overstate or understate the difference depending on which direction the comparison runs.
What is not established
No randomized head-to-head trial has compared retatrutide with semaglutide or with tirzepatide on weight loss, glycaemic control, or adverse events. No published study has measured the three agents against each other in the same protocol. Claims of superiority for retatrutide over either comparator, in any population or for any outcome, are therefore not supported by direct evidence, and the class-level finding that these agents are efficacious for weight loss 7 does not distinguish among them. Even the indirect picture is incomplete: the review's conclusion applies to adults with overweight or obesity without diabetes 7, while the trial population described above was defined by type 2 diabetes and a BMI of 25 to 50 kg/m2 1, so the two bodies of evidence do not describe interchangeable groups. Researchers designing a comparison should treat agent selection, population matching, and endpoint definition as separate decisions, and should expect that any ranking they produce rests on assumption rather than randomization. For background on how to read effect sizes across non-randomized comparisons, the Research Literacy Guide covers the relevant caveats.
Eligibility, endpoints, and clinical criteria used in trials
What the enrolled populations actually looked like
The retatrutide trial literature describes a compound built on triple receptor activity. Retatrutide is a single peptide with agonist activity at the GIP, GLP-1, and glucagon receptors, a mechanistic profile that distinguishes it from earlier incretin-based molecules 1. For contrast, tirzepatide is a dual agonist of GLP-1 and GIP receptors, engaging two of the same three targets but not the glucagon receptor 2. A separate peer-reviewed characterization confirms retatrutide as an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors, which is the description most commonly reproduced in review articles on the class 3.
That receptor profile matters for how eligibility is framed. A trial enrolling participants for a glucagon-receptor-active agent is not enrolling the same population as one testing a pure GLP-1 agonist, because the metabolic readouts of interest differ. Retatrutide and survodutide enable simultaneous activation of the glucagon and GLP-1 receptors, which places both compounds in a mechanistic category where hepatic and energy-expenditure endpoints become plausible primary targets rather than secondary curiosities 5. By comparison, maritide blocks the GIP receptor and activates the GLP-1 receptor, an inverse arrangement on the GIP arm that illustrates how much the class has diverged 5.
Endpoints used in the retatrutide program
Two endpoint families appear in the retatrutide evidence. The first is body weight. At 24 weeks, the least-squares mean percentage change in body weight was -17.5% in the 12-mg retatrutide group versus -1.6% in the placebo group, a between-group separation that is large by the standards of 24-week obesity intervention data 3. The second is hepatic. The primary objective of the substudy was to assess mean relative change from baseline in liver fat at 24 weeks, which indicates that at least one retatrutide substudy was powered around an imaging-based liver endpoint rather than weight alone 4.
Safety endpoints were reported in the same body of work. The most common adverse events in the retatrutide groups were gastrointestinal, a pattern consistent with the incretin class broadly and relevant to any protocol that specifies tolerability monitoring 3.
| Domain | Endpoint or criterion | Result or specification | Source |
|---|---|---|---|
| Receptor pharmacology | GIP, GLP-1, glucagon agonism | Single peptide, triple agonist | 1 |
| Receptor pharmacology | GIP and GLP-1 agonism | Dual agonist comparator (tirzepatide) | 2 |
| Receptor pharmacology | GIP, GLP-1, glucagon agonism | Confirmed in independent characterization | 3 |
| Receptor pharmacology | Glucagon plus GLP-1 activation | Shared with survodutide | 5 |
| Receptor pharmacology | GIP blockade plus GLP-1 activation | Maritide, inverse GIP arrangement | 5 |
| Efficacy | Body weight change at 24 weeks | -17.5% (12 mg) vs -1.6% (placebo) | 3 |
| Efficacy | Liver fat, relative change from baseline | Primary objective of substudy at 24 weeks | 4 |
| Safety | Adverse event profile | Predominantly gastrointestinal | 3 |
| Development stage | Phase 3 progression as obesity treatment | Cagrisema and retatrutide | 6 |
What should not be assumed
Cagrisema and retatrutide have progressed to phase 3 trials as obesity treatments, which establishes the development stage but not the enrollment criteria used at that stage 6. No published study in this evidence set reports the specific inclusion thresholds, age ranges, BMI cutoffs, comorbidity requirements, or exclusion rules applied to Canadian participants, and none reports a Canadian site list. Researchers should not import eligibility language from semaglutide or tirzepatide labeling and treat it as transferable to retatrutide, because the glucagon component changes the metabolic rationale and the trial populations were defined around different endpoints. Where a protocol needs a validated inclusion feature, the only features supported here are the receptor targets, the two endpoint families, and the adverse event pattern. Everything else is undocumented. For background on how receptor-level claims are read and graded, the Research Literacy Guide is a reasonable starting point.
Safety, monitoring, and dose-related uncertainty
The published safety picture for retatrutide is dominated by tolerability rather than organ toxicity. In the trial data reviewed, most adverse events reported were gastrointestinal-related 7. That is a broad category, and it matters for anyone designing a study protocol: nausea, vomiting, diarrhea and constipation are the events that drive dropout and dose interruption in incretin-class research, not laboratory abnormalities. A trial that reports "most AEs were GI" without disaggregating severity, duration and whether events clustered in the titration window leaves the practical question open. Researchers planning endpoints should expect GI tolerability to be the binding constraint on retention, and should power accordingly rather than treating it as background noise.
What expert commentary flags for monitoring
A peer-reviewed commentary on this compound's safety data identifies a wider set of domains than the GI signal alone: muscle strength, bone density and fractures, exercise capacity, gastrointestinal motility, retained gastric contents and anesthesia, pancreatic and biliary tract disorders, and cancer risk 5. Read that list carefully. Several of these are not captured by routine adverse-event reporting at all. Muscle strength and exercise capacity require functional testing, not a symptom diary. Bone density requires imaging at baseline and follow-up. Retained gastric contents is an anesthesia-planning concern, which means it surfaces in surgical settings rather than in a metabolic trial's own safety tables. Pancreatic and biliary events and cancer risk are long-latency questions that a 24- or 48-week trial cannot answer by design. The commentary's value is that it names domains a short study would systematically miss, not that it establishes harm in any of them.
Dose-response: what is and is not established
The dose-response relationships of retatrutide with respect to side effects, safety, and efficacy for treating obesity were not known 3. This is the central uncertainty, and it cuts both ways. It does not mean no dose relationship exists; it means the published work had not characterized one. That distinction matters for procurement and protocol design, because a researcher cannot currently justify a dose selection on the basis of a documented safety-efficacy tradeoff curve. One dose-related signal was observed: dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter 3. The transient shape of that curve is worth noting for anyone scheduling cardiac monitoring, since a single late timepoint would misrepresent the trajectory.
What the evidence does not establish
Several things commonly asserted about this compound are not supported by the trial data. No published study has established a contraindication profile for retatrutide, and none has measured long-term harms beyond the trial windows reported. The expert commentary's monitoring list is a set of domains flagged for attention, not a set of confirmed adverse outcomes 5. Similarly, the finding that normal liver fat was achieved at 24 weeks by 86% of participants receiving retatrutide 12 mg 4 is a hepatic imaging endpoint in a specific dose arm, not evidence of hepatic safety across doses, and it says nothing about what happens after treatment stops. A reader evaluating this material should treat the 12 mg hepatic result and the 24-week heart rate peak as timepoint-bound observations, and treat GI event frequency as the only tolerability signal with enough consistency to plan around. For handling and documentation practices that support reproducible protocols, see the Quality and Testing page.
Storage, formulation questions, and product-page label language
Product pages for research peptides carry a layer of interface text that has nothing to do with the chemistry in the vial. "Add to cart," "in stock," "quick view," "new arrival," "select options," "read more," "our price," "express shipping," and "rating 5/5" are commerce signals. They describe how a storefront is built and how a buyer moves through it. None of them is an authorization, a certificate of analysis, or a statement about what is inside the container. A listing that says "in stock" tells you the seller believes it can ship a unit today. It does not tell you the material was tested, that it is what the label says, or that anyone reviewed it. "Rating 5/5" is a customer-facing aggregate, and on most platforms it reflects order experience, not analytical verification. "New arrival" is a merchandising flag tied to when an item was added to a catalog, not to when it was synthesized or how it has been held since. "Quick view" and "read more" are navigation controls. "Our price" and "express shipping" are commercial terms. Treating any of these as evidence of quality is a category error, and it is one of the more common ones in procurement.
The phrase "metabolic research" deserves the same scrutiny. It is a category label used to sort products on a storefront. It is not a study design, an indication, or a regulatory status. A product filed under that heading has been placed there by the seller.
What the clinical literature actually reports
The reason retatrutide draws research interest is a body of trial data, not a product page. In a peer-reviewed trial, bodyweight decreased dose dependently with retatrutide at 36 weeks 1. That is a dose-response relationship measured at a defined timepoint in a defined population. The same trial enrolled 98 participants 4. Ninety-eight is a small number. It supports a signal, not a settled effect size, and it says nothing about how any particular vial was manufactured, shipped, or stored.
The broader incretin literature is where most of the adjacent questions live. Cardiorenal benefits of GLP-1 receptor agonists have been established in select patient populations, per a peer-reviewed study 5. That finding belongs to GLP-1 receptor agonists as a class and to specific populations, not to retatrutide, and not to any research listing. The same source notes that ongoing trials are investigating GLP-1 agents for metabolic liver disease 5, which is to say the question is open and being tested, not answered.
One peer-reviewed study proposes tailored resistance exercise training as an adjunct to incretin therapy to preserve lean mass while achieving fat loss 2. That is a proposed intervention strategy from the authors of that paper. It is a hypothesis about how to pair a drug with training, and it is not a dosing instruction, a storage requirement, or a claim about any commercial product.
What is not documented here
No source cited in this section validates stability, lyophilized storage conditions, or reconstitution requirements for consumer purchase. That gap is real and it matters. A product page can say "in stock" and "express shipping" and still tell you nothing about cold-chain handling, desiccant condition, or how long the material sat in a warehouse. Those are questions for a certificate of analysis and a storage protocol, not a storefront.
| Interface term | What it actually signals | What it does not establish |
|---|---|---|
| Add to cart | Storefront supports order entry | Product identity, purity, or authorization |
| In stock | Seller expects to ship a unit | Analytical testing or chain of custody |
| Quick view | Navigation control | Any product attribute |
| New arrival | Recent catalog addition | Synthesis date or storage history |
| Rating 5/5 | Aggregated buyer feedback | Verified quality or composition |
| Our price | Commercial term | Regulatory status |
| Express shipping | Fulfillment option | Cold-chain integrity |
| Metabolic research | Seller-assigned category | Study design or indication |
| Select options | Variant selector | Anything about the material |
| Read more | Expandable content control | Independent verification |
For the underlying handling questions, the Peptide Storage Guide covers general practice, and the Quality and Testing page describes what documentation accompanies a lot. Neither replaces reading a specific certificate.
What the Evidence Does Not Establish
The retatrutide literature is early, small, and narrower than the sourcing conversation around it suggests. A peer-reviewed study reported that retatrutide treatment for 48 weeks in adults with obesity produced substantial reductions in body weight 3. That is a real signal. It is not a completed safety picture, and it does not tell a reader anything about the compound's regulatory position in Canada, its long-term tolerability, or how it compares head to head against approved agents.
Tolerability Is Characterized, Not Settled
In the same trial, mild-to-moderate gastrointestinal adverse events were reported in 67 of 190 participants in the retatrutide groups 1. That is roughly a third of exposed participants reporting GI effects of mild to moderate severity. It says nothing about events beyond the trial window, nothing about rebound after discontinuation, and nothing about whether the profile holds in populations excluded from the study. No published study has measured retatrutide's cardiovascular outcomes, and none has followed participants long enough to speak to durability.
The Comparator Base Is Different From the Retatrutide Base
For context, a peer-reviewed analysis of tirzepatide reported up to 22.5% weight loss in phase 3 obesity trials 6. A separate peer-reviewed review covered 26 randomized controlled trials with 15,491 participants 7. Those numbers describe tirzepatide and the broader incretin trial base, not retatrutide. Pooling them into a single efficacy expectation for retatrutide is a category error, and it happens constantly in sourcing discussions. Liraglutide and semaglutide are GLP-1 receptor agonists 2, which places them in a mechanistic family that retatrutide's triple-agonist design does not share. Mechanism does not transfer across molecules.
What Remains Unmeasured
No published study establishes retatrutide's Canadian regulatory status, its availability through any licensed channel, or its shelf-life under real-world handling. Research-use material is not a therapeutic and carries no dosing guidance. Anyone treating a 48-week obesity trial result as a finished clinical profile is reading past the evidence. For handling and documentation standards that do apply to research material, see the Quality and Testing page.
Analytical Documentation and Quality Verification
A certificate of analysis for retatrutide is only as useful as the reader's ability to interpret it. The document should identify the lot, the analytical method used for each test, and the acceptance criterion the result was judged against. A purity figure without a stated method is not verifiable.
Purity and Identity
Reverse-phase HPLC is the standard method for reporting peptide purity, and the chromatogram should be included rather than summarized as a single percentage. Mass spectrometry confirms that the principal peak corresponds to the expected molecular mass, which distinguishes the target peptide from a closely related impurity that co-elutes. Both tests answer different questions: HPLC quantifies how much of the material is the main peak, while MS confirms what that peak is. A researcher evaluating retatrutide (10mg) or a larger format should expect both.
What the Certificate Cannot Tell You
Analytical release testing does not establish biological activity, sterility, or endotoxin content unless those assays are listed explicitly. No published study has measured how a given lot's purity translates into in vivo potency, and the certificate is not designed to. The Quality and Testing page covers the specific assays run on each lot and how results are reported.
Context for the Material
Retatrutide is an investigational incretin-based agent. A 2023 peer-reviewed trial reported that at 24 weeks retatrutide reduced HbA1c significantly more than placebo in all dose groups except the 0.5 mg group 1. Incretin agonist peptides as a class induce approximately 15 to 24 percent weight loss in adults with overweight and obesity, according to a peer-reviewed review 2. The same review notes these agents cause rapid and significant loss of lean mass, roughly 10 percent or about 6 kg 2, and that supervised resistance training lasting more than 10 weeks can produce large increases in lean mass of about 3 kg 2. Semaglutide 2.4 mg produces mean weight loss of 15 to 17 percent, that review also reports 6. A separate peer-reviewed study found liver fat reductions were significantly related to changes in body weight, abdominal fat and metabolic measures 4. GLP-1 receptor agonists were originally developed for type 2 diabetes and obesity, per that same peer-reviewed work 5. Cagrisema, a combination of a GLP-1 receptor agonist and an amylin receptor agonist, is a distinct construct from retatrutide 6. Combining aerobic exercise with liraglutide after a low-calorie diet improved weight loss maintenance compared with either alone, one peer-reviewed study reported 2. None of this substitutes for lot-level documentation.
References
- Rosenstock J et al. (2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (London, England). PMID: 37385280. PubMed
- Locatelli JC et al. (2024) Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?. Diabetes care. PMID: 38687506. PubMed
- Jastreboff AM et al. (2023) Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England journal of medicine. PMID: 37366315. PubMed
- Sanyal AJ et al. (2024) Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine. PMID: 38858523. PubMed
- Drucker DJ. (2024) Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes care. PMID: 38843460. PubMed
- Melson E et al. (2025) What is the pipeline for future medications for obesity?. International journal of obesity (2005). PMID: 38302593. PubMed
- Moiz A et al. (2025) Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Annals of internal medicine. PMID: 39761578. PubMed
*All materials referenced on this page are supplied for laboratory research use only.
They are not medicines, are not approved for human or veterinary use, and nothing here
is medical advice. Findings described above belong to the model systems in which they
were observed. Reviewed by the Volta Peptides Research Team.*
